Eveliqure

1 known investors

Eveliqure Biotechnologies develops vaccines to prevent diarrhoeal diseases in both travellers and people in low- and middle-income endemic regions, using a live attenuated Shigella strain engineered for broad protection against multiple pathogens. Its lead candidate, ShigETEC, is an oral vaccine targeting Shigella and enterotoxigenic E. coli (ETEC).